LY2216684 + Placebo + Escitalopram
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Major Depressive Disorder
Conditions
Major Depressive Disorder
Trial Timeline
Dec 1, 2006 → Mar 1, 2008
NCT ID
NCT00420004About LY2216684 + Placebo + Escitalopram
LY2216684 + Placebo + Escitalopram is a phase 2 stage product being developed by Eli Lilly for Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00420004. Target conditions include Major Depressive Disorder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00420004 | Phase 2 | Completed |
Competing Products
20 competing products in Major Depressive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 23 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 33 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 85 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 52 |
| LY2216684 + Sertraline | Eli Lilly | Phase 1 | 33 |
| LY2216684 + Placebo + Lorazepam | Eli Lilly | Phase 1 | 33 |
| LY2216684 + SSRI | Eli Lilly | Phase 3 | 77 |
| Duloxetine | Eli Lilly | Approved | 85 |